Skip to main content
SpringerLink
Log in

ICER reports on JAK inhibitors for RA, and acute migraine treatments

  • News item
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Institute for Clinical and Economic Review. ICER Issues Final Report and Policy Recommendations on JAK Inhibitors for Rheumatoid Arthritis Internet Document : 9 Jan 2020. Available from: URL: https://icer-review.org/announcements/icer-issues-final-report-and-policy-recommendations-for-rheumatoid-arthritis-therapies/

  2. Institute for Clinical and Economic Review. ICER Releases Evidence Report on Acute Treatments for Migraine Internet Document : 10 Jan 2020. Available from: URL: https://icer-review.org/announcements/acute_migraine_evidence_report/

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

ICER reports on JAK inhibitors for RA, and acute migraine treatments. PharmacoEcon Outcomes News 845, 33 (2020). https://doi.org/10.1007/s40274-020-6536-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-020-6536-8

Search

Navigation